The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of investigational drug Colchicine combined with
conventional lenalidomide based therapy in multiple myeloma subjects who had received
first-line therapy (including Chimeric antigen receptor T-Cell immunotherapy (CART)
treatment), and to evaluate the quality of life of the patients.